---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-23-000020"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2023-04-03T23:59:59+00:00"
generated_at: "2026-06-17T06:50:55.067170+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Supernus borrows $93M under credit line, repays $402.5M convertible notes due 2023

## Summary
- Borrowed $93M from UBS Bank USA on March 30, 2023 under a $150M revolving credit line.
- Used proceeds plus available cash to repay the full $402.5M principal and $1.3M interest on its 0.625% Convertible Senior Notes due April 2023.
- Credit line is secured by company accounts, securities, and investment property held at UBS.
- Following repayment, the 2023 Notes are no longer outstanding.

## SEC filing metadata
- accession: 0001356576-23-000020
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2023-04-03T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000020/0001356576-23-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000020/supn-20230330.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-23-000020
- JSON: https://secwatch.observer/filing/0001356576-23-000020.json
- Plain text: https://secwatch.observer/filing/0001356576-23-000020.txt

## Key facts
- Debt Financings
  SUPERNUS PHARMACEUTICALS, INC. incurred credit facility of $93 million with UBS Bank USA at variable rate.
  - Instrument: credit facility
  - Principal: $93 million
  - Counterparty: UBS Bank USA
  - Rate: variable rate
  - Event: incurrence
  source text: On March 30, 2023 the Company borrowed $93 million pursuant to the credit line agreement with UBS Bank USA ("UBS") dated as of February 8, 2023 (the "Credit Line").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000020/0001356576-23-000020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.